Table 3.
Vaccine effectiveness against infection of any severity after the second vaccine dose across all SARS-CoV-2 variants. The numbers only reflect vaccine effectiveness against infection, independent of symptoms.
| Weeks after last dose | Second dose, any vaccine brand (%, 95% CI) | Second dose, BNT162b2 (Pfizer-BioNTech; %, 95% CI) |
| 4 | 87.8 (64.3 to 95.8) | 91.2 (70.4 to 97.4) |
| 8 | 78.5 (60.5 to 88.3) | 72 (50.1 to 84.3) |
| 12 | 67.4 (47.8 to 79.6) | 66.8 (47.2 to 79.1) |
| 16 | 65.6 (49.9 to 76.4) | 63.3 (46.5 to 74.8) |
| 20 | 62.1 (47.5 to 72.6) | 50.4 (23.1 to 63.7) |
| 24 | 42.8 (26 to 55.8) | 42.3 (24.7 to 55.8) |
| 28 | 13 (7.3 to 29.5) | 2.5 (−23.8 to 23.1) |
| 32 | 14 (4.3 to 29.1) | 10.4 (−11.5 to 28) |
| 36 | 25.5 (10.4 to 38) | 21.3 (2.7 to 36.3) |
| 40 | 35.3 (22.8 to 45.8) | 31.1 (15.5 to 43.8) |
| 44 | 34.9 (22.6 to 45.3) | 30.2 (14.8 to 42.8) |
| 48 | 37.9 (26.5 to 47.6) | 37.2 (23.5 to 48.5) |